Cargando…

Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma

WHO 2/3 glioma is a common intracranial tumor that seriously affects the quality of life and survival time of patients. Previous studies have shown that the tricarboxylic acid (TCA) cycle is closely related to the occurrence and development of glioma, while recent studies have shown that cuproptosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Zhang, Zhang, Shenqi, Cai, Jiayang, Ye, Liguo, Gao, Lun, Wang, Yixuan, Tong, Shiao, Sun, Qian, Wu, Yu, Xiong, Xiaoxing, Chen, Qianxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434124/
https://www.ncbi.nlm.nih.gov/pubmed/36059638
http://dx.doi.org/10.3389/fonc.2022.967159
_version_ 1784780799669698560
author Ye, Zhang
Zhang, Shenqi
Cai, Jiayang
Ye, Liguo
Gao, Lun
Wang, Yixuan
Tong, Shiao
Sun, Qian
Wu, Yu
Xiong, Xiaoxing
Chen, Qianxue
author_facet Ye, Zhang
Zhang, Shenqi
Cai, Jiayang
Ye, Liguo
Gao, Lun
Wang, Yixuan
Tong, Shiao
Sun, Qian
Wu, Yu
Xiong, Xiaoxing
Chen, Qianxue
author_sort Ye, Zhang
collection PubMed
description WHO 2/3 glioma is a common intracranial tumor that seriously affects the quality of life and survival time of patients. Previous studies have shown that the tricarboxylic acid (TCA) cycle is closely related to the occurrence and development of glioma, while recent studies have shown that cuproptosis, a novel programmed death pathway, is closely related to the inhibition of the TCA cycle. In our study, eight of ten cuproptosis-related genes (CRGs) were found to be differentially expressed between normal and WHO 2/3 glioma tissues. Through the LASSO algorithm, the cuproptosis-associated risk signatures (CARSs) were constructed, which can effectively predict the prognosis of WHO 2/3 glioma patients and are closely related to clinicopathological features. We analyzed the relationship between risk score and immune cell infiltration through Xcell, ssGSEA, TIMER database, and immune checkpoint molecules. In addition, the relationship between risk score and chemotherapeutic drug sensitivity was also investigated. The prognosis-related independent risk factors FDX1 and CDKN2A identified from CARSs are considered potential prognostic biomarkers for WHO 2/3 glioma. The clinical prognosis model based on cuproptosis is expected to provide an effective reference for the diagnosis and treatment of clinical WHO 2/3 glioma patients.
format Online
Article
Text
id pubmed-9434124
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94341242022-09-02 Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma Ye, Zhang Zhang, Shenqi Cai, Jiayang Ye, Liguo Gao, Lun Wang, Yixuan Tong, Shiao Sun, Qian Wu, Yu Xiong, Xiaoxing Chen, Qianxue Front Oncol Oncology WHO 2/3 glioma is a common intracranial tumor that seriously affects the quality of life and survival time of patients. Previous studies have shown that the tricarboxylic acid (TCA) cycle is closely related to the occurrence and development of glioma, while recent studies have shown that cuproptosis, a novel programmed death pathway, is closely related to the inhibition of the TCA cycle. In our study, eight of ten cuproptosis-related genes (CRGs) were found to be differentially expressed between normal and WHO 2/3 glioma tissues. Through the LASSO algorithm, the cuproptosis-associated risk signatures (CARSs) were constructed, which can effectively predict the prognosis of WHO 2/3 glioma patients and are closely related to clinicopathological features. We analyzed the relationship between risk score and immune cell infiltration through Xcell, ssGSEA, TIMER database, and immune checkpoint molecules. In addition, the relationship between risk score and chemotherapeutic drug sensitivity was also investigated. The prognosis-related independent risk factors FDX1 and CDKN2A identified from CARSs are considered potential prognostic biomarkers for WHO 2/3 glioma. The clinical prognosis model based on cuproptosis is expected to provide an effective reference for the diagnosis and treatment of clinical WHO 2/3 glioma patients. Frontiers Media S.A. 2022-08-18 /pmc/articles/PMC9434124/ /pubmed/36059638 http://dx.doi.org/10.3389/fonc.2022.967159 Text en Copyright © 2022 Ye, Zhang, Cai, Ye, Gao, Wang, Tong, Sun, Wu, Xiong and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ye, Zhang
Zhang, Shenqi
Cai, Jiayang
Ye, Liguo
Gao, Lun
Wang, Yixuan
Tong, Shiao
Sun, Qian
Wu, Yu
Xiong, Xiaoxing
Chen, Qianxue
Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma
title Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma
title_full Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma
title_fullStr Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma
title_full_unstemmed Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma
title_short Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma
title_sort development and validation of cuproptosis-associated prognostic signatures in who 2/3 glioma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434124/
https://www.ncbi.nlm.nih.gov/pubmed/36059638
http://dx.doi.org/10.3389/fonc.2022.967159
work_keys_str_mv AT yezhang developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma
AT zhangshenqi developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma
AT caijiayang developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma
AT yeliguo developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma
AT gaolun developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma
AT wangyixuan developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma
AT tongshiao developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma
AT sunqian developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma
AT wuyu developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma
AT xiongxiaoxing developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma
AT chenqianxue developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma